Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laboratorios Farmaceuticos RoviLABFF 99 Capex-to-Operating-Income is 0.79 as of Jun. 2026, which is 80% above its 10-year median of 0.44. GuruFocus rates LABFF with a GF Score™ of 99/100 and a GF Value™ of $85.88 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 508 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks worse than 53.15% on this metric.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Laboratorios Farmaceuticos Rovi Capex-to-Operating-Income Related Terms
Laboratorios Farmaceuticos Rovi Capex-to-Operating-Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LABFF vs ZTS, UTHR, VTRS: Capex-to-Operating-Income Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Capex-to-Operating-Income vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Capex-to-Operating-Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Income of 0.79 mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Capex-to-Operating-Income of 0.79 as of Jun. 2026. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 80% above median its historical median of 0.44. Over the past decade, Laboratorios Farmaceuticos Rovi's Capex-to-Operating-Income has ranged from 0.20 to 1.52. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #270 out of 508 companies in the Drug Manufacturers industry, placing it in the top 53.1%.
Is Laboratorios Farmaceuticos Rovi's Capex-to-Operating-Income too high?
Laboratorios Farmaceuticos Rovi's current Capex-to-Operating-Income of 0.79 is 80% above median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 1.52. The Drug Manufacturers industry median Capex-to-Operating-Income is 0.39. Laboratorios Farmaceuticos Rovi's value of 0.79 is 102.6% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #270 out of 508 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Capex-to-Operating-Income compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #270 out of 508 companies for Capex-to-Operating-Income. This places Laboratorios Farmaceuticos Rovi in the lower half of its industry. The industry median Capex-to-Operating-Income is 0.39. Laboratorios Farmaceuticos Rovi's value of 0.79 is 102.6% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Capex-to-Operating-Income has ranged from 0.20 to 1.52 over the past decade. While the company's 10-year median is 0.44 vs. the industry median of 0.39, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Income for a Drug Manufacturers company?
The median Capex-to-Operating-Income among Drug Manufacturers companies is 0.39, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Income significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Capex-to-Operating-Income of 0.79 is 102.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Income mean?
A high Capex-to-Operating-Income can signal that a stock is expensive relative to its fundamentals. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Capex-to-Operating-Income is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Capex-to-Operating-Income is 0.79, which is 80% above median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (LABFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $85.88, compared to a current price of $67.17 — trading 21.8% below its estimated fair value. The current Capex-to-Operating-Income is 0.79, which is 80% above median its 10-year median of 0.44 and 102.6% above the Drug Manufacturers industry median of 0.39. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Income calculated?
Capex-to-Operating-Income is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Capex-to-Operating-Income is 0.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be undervalued.
The current stock price of $67.17 is trading 21.8% below its estimated GF Value™ of $85.88.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Undervalued.
Key valuation signals for LABFF:
Capex-to-Operating-Income: 0.79 (80% above median its 10-year median of 0.44)
GF Value™: $85.88 vs. price of $67.17 (21.8% below fair value)
Industry Position: 102.6% above the Drug Manufacturers median (#270 of 508)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
99GF Score
Get the complete analysis for LABFF
Capex-to-Operating-Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
